5 Large Cap Stocks With Impressive Bottom Line Profitability And Minimal Debt

by: ZetaKap

Are you looking for large-cap companies that still have room to grow? Do you prefer companies with strong profits? In search of companies that can manage their debt well? If so, here's a list you might be interested in.

Net Margin is a profitability metric that illustrates, by percentage, how much of every dollar earned gets turned into a bottom line profit. This is just one of many profitability metrics used by investors and analysts to better understand what the company is being left with at the end of the day. Generally, a firm that can expand its net profit margins over a period of time will see its stock price rise as well due to the trend of increasing profitability. Net Margin = Net Income/Total Revenue

The Debt/Equity Ratio illustrates how aggressively a company is financing its growth via debt. The more debt financing that is used in a capital structure, the more volatile earnings can become due to the additional interest expense. Should a company's potentially enhanced earnings fail to exceed the cost associated with debt financing over time, this can lead the company toward substantial trouble.

We first looked for Large Cap stocks that have achieved strong bottom line profitability (Net Margin [TTM]>10%) and that operate with little to no debt (D/E Ratio<.3). We did not screen out any sectors.

Do you think these large-cap stocks will perform well? Use our list along with your own analysis.

1) Analog Devices Inc. (NASDAQ:ADI)

Sector: Technology
Industry: Semiconductor - Integrated Circuits
Market Cap: $11.26B
Beta: 1.08

Analog Devices Inc. has a Net Margin of 26.94% and Debt/Equity Ratio of 0.23. The short interest was 1.62% as of 04/22/2012. Analog Devices, Inc. engages in the design, manufacture, and marketing of analog, mixed-signal, and digital signal processing integrated circuits (ICS) used in industrial, automotive, consumer, and communication applications. The company's signal processing products involve in converting, conditioning, and processing real-world phenomena, such as temperature, pressure, sound, light, speed, and motion into electrical signals. Its product range includes data converters, amplifiers and linear products, radio frequency ICs, power management products, sensors based on micro-electro mechanical systems technology and other sensors, and processing products.

2) Altera Corp. (NASDAQ:ALTR)

Sector: Technology
Industry: Semiconductor - Specialized
Market Cap: $11.38B
Beta: 1.15

Altera Corp. has a Net Margin of 34.64% and Debt/Equity Ratio of 0.16. The short interest was 1.56% as of 04/22/2012. Altera Corporation, a semiconductor company, designs, manufactures, and markets programmable logic devices (PLD), HardCopy application-specific integrated circuit (OTC:ASIC) devices, pre-defined design building blocks, and associated development tools. The company's PLDs consist of field-programmable gate arrays (FPGAs) and complex programmable logic devices (CPLDs), which are standard semiconductor integrated circuits or chips to perform desired logic functions in the electronic systems; and HardCopy structured ASIC devices that comprise transition customer designs from high-density FPGAs to low-cost non-programmable implementations for volume production.

Its products primarily include Stratix series high-end, system-level FPGAs; Arria series mid-range transceiver and embedded processor equipped FPGAs; Cyclone series low-cost transceiver and embedded processor equipped FPGAs; MAX series CPLDs; and HardCopy ASICs. The company's products also comprise intellectual property cores in hard and soft forms that are pre-verified building blocks that execute system-level functions; and development tools consisting primarily of the Quartus II software for design entry, design compilation, design verification, and device programming.

3) Applied Materials Inc. (NASDAQ:AMAT)

Sector: Technology
Industry: Semiconductor Equipment & Materials
Market Cap: $15.20B
Beta: 1.13

Applied Materials Inc. has a Net Margin of 15.35% and Debt/Equity Ratio of 0.23. The short interest was 1.10% as of 04/22/2012. Applied Materials, Inc. provides manufacturing equipment, services, and software to the semiconductor, flat panel display, solar photovoltaic (PV), and related industries worldwide. The company's Silicon Systems Group segment offers a range of manufacturing equipment used to fabricate semiconductor chips or integrated circuits. This segment provides systems that perform primary processes used in chip fabrication, including atomic layer deposition, chemical vapor deposition, physical vapor deposition, electrochemical deposition, rapid thermal processing, chemical mechanical planarization, wet cleaning, and wafer metrology and inspection, as well as systems that etch or inspect circuit patterns on masks used in the photolithography process.

4) Franklin Resources Inc. (NYSE:BEN)

Sector: Financial
Industry: Asset Management
Market Cap: $26.50B
Beta: 1.47

Franklin Resources Inc. has a Net Margin of 25.55% and Debt/Equity Ratio of 0.25. The short interest was 1.85% as of 04/22/2012. Franklin Resources Inc. is a publicly owned asset management holding company. The firm provides its services to individuals, institutions, pension plans, trusts, and partnerships. It manages, through its subsidiary, separate client-focused equity, fixed income, and balanced portfolios.

5) Biogen Idec Inc. (NASDAQ:BIIB)

Sector: Healthcare
Industry: Biotechnology
Market Cap: $30.37B
Beta: 0.84

Biogen Idec Inc. has a Net Margin of 25.09% and Debt/Equity Ratio of 0.17. The short interest was 0.98% as of 04/22/2012. Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include the AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); TYSABRI to treat relapsing MS; FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability.

*Company profiles were sourced from Finviz.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.